Roche’s Perjeta Witnessed Solid Growth in Q1 2018



Perjeta revenue trends

Roche’s (RHHBY) Perjeta generated first-quarter revenues of 613.0 million Swiss francs, compared to 524.0 million Swiss francs in the first quarter of 2017. This reflected ~18.0% YoY (year-over-year) growth on a constant exchange rate basis.

In the United States, Europe, and Japan, Perjeta generated first-quarter revenues of 287.0 million Swiss francs, 215.0 million Swiss francs, and 28.0 million Swiss francs, respectively, which reflected ~18.0%, ~13.0%, and 11.0% YoY growth.

Article continues below advertisement

Increased demand for Perjeta in the neoadjuvant and metastatic setting primarily pushed the revenue growth of the drug in the US market. In December 2017, the FDA’s approval of Perjeta, in combination with Herceptin and chemotherapy for the treatment of individuals with HER-2 positive early breast cancer who are at high risk of recurrence, also propelled the drug’s revenue growth in the first quarter.

Recent developments

In April, the EMA’s (European Medicines Agency) CHMP (Committee for Medicinal Products for Human Use) recommended a positive opinion for approval of combination therapy consisting of Perjeta, Herceptin, and chemotherapy for post-surgery treatment of adult individuals with HER2-positive early breast cancer (or eBC) who are at high risk of recurrence.

Roche’s application for label expansion was supported by the data from the Phase 3 APHINITY trial. In the APHINITY trial, at a median follow-up of 45.4 months, Perjeta (in combination with Herceptin and chemotherapy) decreased the risk of invasive breast cancer recurrence or death by 19.0% compared to individuals on Herceptin and chemotherapy.

The study also demonstrated that the Perjeta-based triple regimen reduced the risk of recurrence or death by 23.0% in patients with lymph node-positive disease. In the APHINITY trial, the Perjeta-based triple regimen decreased the risk of recurrence or death by 24.0% in patients with hormone receptor-negative disease.

According to WHO (World Health Organization) and other statistical studies, each year around 100,000 individuals in Europe are diagnosed with HER2-positive breast cancer. Some important drugs for HER2-negative metastatic breast cancer in the market include Novartis’ (NVS) Afinitor and Kisqali, Pfizer’s (PFE) Ibrance, and Eli Lilly’s (LLY) Verzenio.


More From Market Realist